ESR1 and triple-negative breast carcinoma: In addition, there has been relatively little exploration of SDG’s effects on models of triple-negative breast cancer (TNBC), despite epidemiologic data suggesting enterolignans may have a stronger protective effect against mortality from ERα-negative tumors [4].